Leveraging ARV Optimization Opportunities to Unlock National Cost Savings

Updated: Dec 8, 2021


This memo highlights the benefits, market considerations, and potential for savings of three ARV optimization opportunities.

  1. Proactively switch eligible adult second-line patients on protease inhibitors to DTG-based regimens

  2. Ensure transition of pediatric patients to appropriate optimal products as they age and grow

  3. Move to larger, carton-less pack sizes to enable multi-month dispensing


1 view

Related Posts

See All